Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.

ABSTRACT:

Background

Children with severe atopic dermatitis (AD) have a multidimensional disease burden.

Objective

Here we assess the clinically meaningful improvements in AD signs, symptoms, and quality of life (QoL) in children aged 6-11 years with severe AD treated with dupilumab compared with placebo.

Methods

R668-AD-1652 LIBERTY AD PEDS was a randomized, double-blinded, placebo-controlled, parallel-group, phase III clinical trial of dupilumab with concomitant topical corticosteroids (TCS) in children aged 6-11 years with severe AD. This post hoc analysis focuses on 304 patients receiving either dupilumab or placebo with TCS and assessed the percentage of patients considered responsive to dupilumab treatment at week 16.

Results

At week 16, almost all patients receivi

SUBMITTER: Siegfried EC 

PROVIDER: S-EPMC10460374 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature